A Phase 1 interventional study of 90 mg MK-0517 (PS80) and 100 mg MK-0517 (PS80) in Chemotherapy-Induced Nausea and Vomiting and Postoperative Nausea and Vomiting, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-19.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing aprepitant in Postoperative Nausea and Vomiting — 2 open to participants now, 2 under way, none of them phase 3. Aprepitant · Postoperative Nausea and Vomiting.
Among the 27 studies testing aprepitant in Postoperative Nausea and Vomiting, this one is the 8th largest by enrollment, is the only one that started in 2005, is one of 2 in phase 1, and was the 8th registered.
638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.
Browse Postoperative Nausea and Vomiting studies →2 of the 27 studies testing aprepitant in Postoperative Nausea and Vomiting are open now, in 2 countries. Recruiting first, the newest first:
IWK Health Centre · Sites in Canada
Ages 8–19
Endeavor Health · Sites in United States
Ages 18–90
By country, each count listing its studies:
Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 65 Postoperative Nausea and Vomiting studies recruiting now, 22 (34%) set no upper age limit and 37 (57%) stop at 75 or younger; 14 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 4 · Phase 4 14
First in 2005; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 188 is above the median of 112 across 529 interventional studies indexed under Postoperative Nausea and Vomiting.
Median enrollment 115 across the 27 interventional studies. Of the 19 that completed or were terminated, 9 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 5 studies filed under Postoperative Nausea and Vomiting — fewer than ten, so there is no comparison to draw.
2 of the studies testing aprepitant in Postoperative Nausea and Vomiting that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06357234IWK Health CentreAprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery | 2027-03 |
| NCT07639723Endeavor HealthAprepitant to Improve Same Day Discharge for TKA | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies testing aprepitant in Postoperative Nausea and Vomiting, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This 5-part study will evaluate the safety, tolerability, and pharmacokinetics of two formulations of MK-0517 (with and without polysorbate 80) and aprepitant in healthy adults. Parts I to IV of this study will examine different doses of MK-0517 as well as two different formulations of MK-0517 (with and without polysorbate 80). Part V of the study will compare single doses of intravenous non-PS80 MK-0517 to oral 125-mg capsule of aprepitant. The primary hypothesis for Part V of the study is that a single intravenous dose of 100-mg or 115-mg MK-0517 is area under the plasma-time curve (AUC) equivalent to that of the 125-mg oral aprepitant capsule in young healthy participants.
638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.
This study's enrollment of 188 is above the median of 112 across 529 interventional studies indexed under Postoperative Nausea and Vomiting.
Browse Postoperative Nausea and Vomiting studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Compared within Postoperative Nausea and Vomiting, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Vomiting. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 mg MK-0517 (nonpolysorbate 80 formulation \[non-PS80\]) or placebo → 150 mg MK-0517 (non- PS80) or placebo → 125 mg aprepitant
Drug: 100 MK-0517 (PS80) + 2 mg midazolam · Drug: 100 mg MK-0517 (non-PS80) · Drug: 150 mg MK-0517 (Non-PS80) · Drug: Placebo · Drug: 125 mg Aprepitant
100 mg MK-0517 (PS80 formulation \[PS80\]) or placebo → 150 mg MK-0517 (PS80) or placebo → 125 mg aprepitant
Drug: 100 mg MK-0517 (PS80) · Drug: 150 mg MK-0517 (PS80) · Drug: Placebo · Drug: 125 mg Aprepitant
40 mg MK-0517 (non-PS80) or placebo → 40 mg aprepitant
Drug: 40 mg MK-0517 (non-PS80) · Drug: Placebo · Drug: 40 mg Aprepitant
2 mg midazolam → 100 mg MK-0517 (PS80) + 2 mg midazolam
Drug: 100 mg MK-0517 (PS80) · Drug: 2 mg Midazolam
125 mg aprepitant → 90 mg MK-0517 (PS80)
Drug: 90 mg MK-0517 (PS80) · Drug: 40 mg MK-0517 (non-PS80) · Drug: 125 mg Aprepitant
40 mg MK-0517 (non-PS80) → 125 mg aprepitant
Drug: 40 mg MK-0517 (non-PS80) · Drug: 125 mg Aprepitant
40 mg MK-0517 (non-PS80)
Drug: 40 mg MK-0517 (non-PS80)
40 mg MK-0517 (non-PS80 formulation)
Drug: 40 mg MK-0517 (non-PS80)
125 mg aprepitant → 100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80 formulation)
Drug: 100 mg MK-0517 (PS80) · Drug: 115 mg MK-0517 (PS80) · Drug: 125 mg Aprepitant
100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80) → 125 mg aprepitant
Drug: 100 mg MK-0517 (PS80) · Drug: 115 mg MK-0517 (PS80) · Drug: 125 mg Aprepitant
115 mg MK-0517 (PS80) → 125 mg aprepitant → 100 mg MK-0517 (PS80)
Drug: 100 mg MK-0517 (PS80) · Drug: 115 mg MK-0517 (PS80) · Drug: 125 mg Aprepitant
125 mg aprepitant → 115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80)
Drug: 100 mg MK-0517 (PS80) · Drug: 115 mg MK-0517 (PS80) · Drug: 125 mg Aprepitant
100 mg MK-0517 (PS80) → 125 mg aprepitant → 115 mg MK-0517 (PS80)
Drug: 100 mg MK-0517 (PS80) · Drug: 115 mg MK-0517 (PS80) · Drug: 125 mg Aprepitant
115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80) → 125 mg aprepitant
Drug: 100 mg MK-0517 (PS80) · Drug: 115 mg MK-0517 (PS80) · Drug: 125 mg Aprepitant
MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes
MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.
MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
Placebo matching MK-0517
Aprepitant, oral, tablet, single dose
Aprepitant oral tablet, single dose
Midazolam oral tablet, single dose
Area Under the Plasma-Time Curve (AUC[0 to Infinity]) for Aprepitant and MK-0517 for Study Part V
AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time. The AUC(0-inf) bioequivalence was evaluated for single doses of 100 and 115 mg MK-0517 PS80, IV and that of an oral 125-mg capsule of aprepitant. Period I to IV populations are not included in the outcome analysis because those were formulation and dose-finding/dose confirmation arms.
Time frame: Up to 72 Hours Post Dose
One Investigator in the United States. Primary therapy period: 31-Jan-2005 to 01-Dec-2005.
| Milestone | Part I, Panel A | Part I, Panel B | Part I, Panel C | Part II | Part III, Panel 1, Treatment Sequence 1 | Part III, Panel 1, Treatment Sequence 2 | Part III, Panel 2 | Part IV | Part V, Treatment Sequence 1 | Part V, Treatment Sequence 2 | Part V, Treatment Sequence 3 | Part V, Treatment Sequence 4 | Part V, Treatment Sequence 5 | Part V, Treatment Sequence 6 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 14 | 16 | 14 | 8 | 17 | 17 | 12 | 14 | 12 | 14 | 12 | 14 | 12 | 12 |
| Completed | 14 | 14 | 14 | 8 | 14 | 14 | 11 | 14 | 12 | 13 | 9 | 9 | 10 | 11 |
| Not completed | 0 | 2 | 0 | 0 | 3 | 3 | 1 | 0 | 0 | 1 | 3 | 5 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 0 | 3 | 3 | 1 | 0 | 0 | 1 | 3 | 5 | 2 | 1 |
AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time. The AUC(0-inf) bioequivalence was evaluated for single doses of 100 and 115 mg MK-0517 PS80, IV and that of an oral 125-mg capsule of aprepitant. Period I to IV populations are not included in the outcome analysis because those were formulation and dose-finding/dose confirmation arms.
| ng*hr/mL | Aprepitant (125 mg) | MK-0517 (100 mg) | MK-0517 (115 mg) |
|---|---|---|---|
| Area Under the Plasma-Time Curve (AUC[0 to Infinity]) for Aprepitant and MK-0517 for Study Part V | 29215 ± 15731 | 24961 ± 10477 | 31724 ± 14287 |
Collected over Up to 30 days after the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 90 mg MK-0517 (PS80) | — | 0/31 (0%) | 8/31 (25.8%) |
| 100 mg MK-0517 (PS80) | — | 0/82 (0%) | 8/82 (9.8%) |
| 100 mg MK-0517 (PS80) + 2 mg Midazolam | — | 0/8 (0%) | 5/8 (62.5%) |
| 115 mg MK-0517 (PS80) | — | 0/66 (0%) | 7/66 (10.6%) |
| 150 mg MK-0517 (PS80) | — | 0/12 (0%) | 3/12 (25%) |
| 40 mg MK-0517 (Non-PS80) | — | 0/36 (0%) | 4/36 (11.1%) |
| 100 mg MK-0517 (Non-PS80) | — | 0/12 (0%) | 3/12 (25%) |
| 150 mg MK-0517 (Non-PS80) | — | 0/11 (0%) | 6/11 (54.5%) |
| Placebo | — | 0/11 (0%) | 2/11 (18.2%) |
| 40 mg Aprepitant | — | 0/14 (0%) | 2/14 (14.3%) |
| 125 mg Aprepitant | — | 0/133 (0%) | 6/133 (4.5%) |
| 2 mg Midazolam | — | 0/8 (0%) | 2/8 (25%) |
| Event | 90 mg MK-0517 (PS80) | 100 mg MK-0517 (PS80) | 100 mg MK-0517 (PS80) + 2 mg Midazolam | 115 mg MK-0517 (PS80) | 150 mg MK-0517 (PS80) | 40 mg MK-0517 (Non-PS80) | 100 mg MK-0517 (Non-PS80) | 150 mg MK-0517 (Non-PS80) | Placebo | 40 mg Aprepitant | 125 mg Aprepitant | 2 mg Midazolam |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SomnolenceNervous system disorders | 0/31 | 0/82 | 5/8 | 0/66 | 0/12 | 0/36 | 0/12 | 0/11 | 0/11 | 0/14 | 0/133 | 2/8 |
| TendernessGeneral disorders | 0/31 | 1/82 | 4/8 | 0/66 | 1/12 | 2/36 | 2/12 | 5/11 | 0/11 | 0/14 | 0/133 | 0/8 |
| HeadacheNervous system disorders | 6/31 | 0/82 | 0/8 | 2/66 | 2/12 | 0/36 | 0/12 | 3/11 | 2/11 | 0/14 | 5/133 | 0/8 |
| SwellingGeneral disorders | 0/31 | 0/82 | 0/8 | 0/66 | 0/12 | 1/36 | 0/12 | 3/11 | 0/11 | 0/14 | 0/133 | 0/8 |
| IndurationGeneral disorders | 0/31 | 0/82 | 1/8 | 0/66 | 0/12 | 3/36 | 2/12 | 2/11 | 0/11 | 0/14 | 0/133 | 0/8 |
| ErythemaSkin and subcutaneous tissue disorders | 0/31 | 0/82 | 1/8 | 0/66 | 0/12 | 3/36 | 2/12 | 2/11 | 0/11 | 0/14 | 0/133 | 0/8 |
| PainGeneral disorders | 0/31 | 0/82 | 0/8 | 0/66 | 0/12 | 2/36 | 2/12 | 0/11 | 0/11 | 0/14 | 0/133 | 0/8 |
| Infusion Site PainGeneral disorders | 0/31 | 7/82 | 1/8 | 5/66 | 0/12 | 1/36 | 1/12 | 1/11 | 0/11 | 0/14 | 0/133 | 0/8 |
| ContusionInjury, poisoning and procedural complications | 0/31 | 0/82 | 1/8 | 0/66 | 1/12 | 0/36 | 0/12 | 0/11 | 1/11 | 0/14 | 0/133 | 0/8 |
| Intraocular Pressure TestInvestigations | 0/31 | 0/82 | 0/8 | 0/66 | 1/12 | 0/36 | 0/12 | 0/11 | 0/11 | 0/14 | 0/133 | 0/8 |
| Age, Continuous(years) | Part I, Panel A | Part I, Panel B | Part I, Panel C | Part II | Part III, Panel 1, Treatment Sequence 1 | Part III, Panel 1, Treatment Sequence 2 | Part III, Panel 2 | Part IV | Part V, Treatment Sequence 1 | Part V, Treatment Sequence 2 | Part V, Treatment Sequence 3 | Part V, Treatment Sequence 4 | Part V, Treatment Sequence 5 | Part V, Treatment Sequence 6 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 31.2 (21 to 45) | 35.2 (23 to 44) | 33.1 (22 to 45) | 36.9 (25 to 45) | 33.2 (19 to 43) | 33.2 (19 to 43) | 32.4 (18 to 45) | 29.4 (18 to 45) | 31.9 (19 to 44) | 33.5 (22 to 44) | 31.3 (22 to 45) | 29.1 (19 to 41) | 30.4 (19 to 45) | 36.5 (20 to 43) | 32.6 (18 to 45) |
| Sex: Female, Male(Participants) | Part I, Panel A | Part I, Panel B | Part I, Panel C | Part II | Part III, Panel 1, Treatment Sequence 1 | Part III, Panel 1, Treatment Sequence 2 | Part III, Panel 2 | Part IV | Part V, Treatment Sequence 1 | Part V, Treatment Sequence 2 | Part V, Treatment Sequence 3 | Part V, Treatment Sequence 4 | Part V, Treatment Sequence 5 | Part V, Treatment Sequence 6 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 7 | 9 | 10 | 5 | 11 | 10 | 10 | 10 | 7 | 11 | 6 | 6 | 4 | 6 | 112 |
| Male | 7 | 7 | 4 | 3 | 6 | 7 | 2 | 4 | 5 | 3 | 6 | 8 | 8 | 6 | 76 |
No study locations are listed for this record.
The record gives a start of Jan 2005, a primary completion of Dec 2005 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 8 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fosaprepitant · Aprepitant
Postoperative Nausea and Vomiting →